Why Is Health Insurance So Expensive in the US

If you've ever stared at a health insurance premium and wondered how a number that large is even possible, you're not alone — and you're not wrong to be suspicious. American healthcare costs more than anywhere else on Earth, by a wide margin. In 2022, the United States spent roughly $12,500 per person on healthcare — more than double what Germany, Canada, or the UK spent per person, according to OECD data. Yet Americans don't live longer or get measurably better care across the board. This article breaks down the structural reasons why — not to assign blame, but because understanding the machinery is the only way to make sense of the bills.

The US Spends Twice as Much as Peer Countries — Where Does It Go?

The short answer: higher prices, not more care. Americans don't visit the doctor more often than people in other wealthy countries. They don't spend more nights in the hospital. What's different is what each visit, procedure, or prescription costs. Four structural factors account for most of the gap: what providers are paid, what drugs cost, how much money is consumed by administration, and the near-total absence of price transparency.

Provider Compensation: American Doctors Earn Far More Than Their Peers Abroad

The average US physician earns approximately $352,000 per year. In the United Kingdom, the comparable figure is around $122,000. In Spain, it's closer to $60,000, according to the 2023 Medscape International Physician Compensation Survey. That's not a rounding error — it's a fundamental difference in what the underlying service costs before insurance, hospitals, or drug companies enter the picture.

Part of this gap is explained by the structure of American medical training. US medical school tuition averages over $200,000 for a four-year program at a private school, and residents often graduate with $200,000–$300,000 in debt before their first day of independent practice. In most peer countries, medical education is heavily subsidized or free. When physicians need to service that debt, they charge more — and when they charge more, insurers pay more, and premiums rise accordingly.

Specialty licensing and certification costs in the US also add layers that don't exist in most other systems. A physician completing a fellowship in cardiology or orthopedics invests years of additional training in a system that pays residents far below market wages. By the time they enter independent practice, the math almost requires high compensation to break even financially.

This isn't a critique of American physicians — it's a description of the pipeline. Change the training cost structure and you'd eventually affect physician compensation. Change physician compensation and you'd affect a significant share of what insurance has to cover.

Drug Prices: Americans Pay Nearly Three Times as Much for the Same Medications

Americans pay on average 2.78 times more for the same brand-name drugs as patients in Germany, France, the UK, Canada, and Japan, according to RAND Corporation research. The same insulin, the same cancer drug, the same cholesterol medication — just priced differently based on where the prescription is filled.

The reason comes down to negotiating power. In most high-income countries, a single national or regional body negotiates drug prices on behalf of the entire population. A drug manufacturer that wants access to the French market has to reach an agreement with the French government, which represents 68 million patients. That creates real leverage. In the United States, there is no equivalent centralized negotiator. Medicare — the federal insurance program for people 65 and older — was legally prohibited from negotiating drug prices at all until the Inflation Reduction Act of 2022, which gave Medicare limited authority to negotiate prices for a small number of high-cost drugs. This was a genuine shift in policy, but it applies to a narrow list and will take years to affect the broader market.

Private insurers negotiate individually with pharmacy benefit managers (PBMs — the middlemen who manage drug formularies and rebates), who negotiate with manufacturers. The resulting system is opaque and fragmented, and the prices Americans pay reflect that fragmentation.

A concrete example: A 30-day supply of Humira (a common biologic drug used for rheumatoid arthritis and Crohn's disease) had a list price of approximately $6,900 in the United States in 2023. In Germany, the same drug cost roughly $1,300. The drug is identical. The difference is entirely structural.

Administrative Overhead: The Hidden Tax on Every Healthcare Dollar

The United States has a multi-payer system — meaning thousands of private insurers, each with its own coverage rules, billing codes, prior authorization requirements, and payment rates. Every hospital and medical practice in the US must maintain staff whose sole job is to navigate this complexity: billing coders, prior authorization coordinators, appeals specialists, credentialing staff. None of these people provide medical care. All of them cost money, and that cost is built into what providers charge.

Estimates of administrative waste in the US healthcare system range from 25% to 35% of total spending — meaning somewhere between one in four and one in three healthcare dollars never touches a patient. In single-payer systems, where one set of rules applies to everyone, administrative costs are dramatically lower because there's no need to maintain separate billing infrastructure for hundreds of different payers.

One visible example of this overhead is prior authorization — the process by which insurers require advance approval before covering certain procedures, medications, or referrals. It is a major source of administrative burden for both providers and patients. If you've ever had a prescription denied or a procedure delayed while your doctor's office spent hours on hold with your insurer, you've experienced this cost directly. You can read more about how to navigate it in our guide to prior authorization and what to do when it's denied.

Price Opacity: No Other Major Industry Works This Way

In almost every other market, prices exist before you buy. You know what a car costs before you sign the loan. You know what a flight costs before you book it. In American healthcare, you often don't know what something costs until weeks after you've received it — and even then, the number on the bill may bear little relationship to what anyone actually pays.

Hospitals maintain what's called a "chargemaster" — an internal price list with often astronomical figures that serve as a starting point for negotiation with insurers. Insured patients are billed at the chargemaster rate, which is then adjusted down to the negotiated rate your insurer has with the hospital. Uninsured patients are often billed the full chargemaster rate, even though no one expects that amount to be collected. The contracted rates between hospitals and insurers are frequently protected as trade secrets.

This opacity makes rational price shopping nearly impossible. Patients can't compare prices, providers have no incentive to compete on price, and employers — who fund most private insurance — often don't know what procedures actually cost their employees until claims are processed. A market without visible prices can't self-correct through competition.

How the Funding Structure Differs From Other Countries

A common misperception is that citizens in countries with universal healthcare get something for free. They don't — they pay for it through taxes, which are meaningfully higher than US tax rates. Other high-income countries collect roughly 20 percentage points more in taxes as a share of their economies than the US does. That revenue funds the coverage infrastructure.

What's different is that the American system layers private premiums, deductibles, copayments, and out-of-pocket costs on top of significant public spending (Medicare, Medicaid, and the VA together account for nearly half of all US healthcare spending, per CMS National Health Expenditure data). Americans pay both — taxes that fund public programs and private premiums for employer or individual coverage — often without realizing the full picture.

What the US Gets for the Money — and What It Doesn't

To be accurate: American healthcare isn't without advantages. The US has more MRI machines per capita than most peer countries. Americans with serious cancers often get faster access to new treatments. Specialty wait times in some areas are shorter than in countries with fully nationalized systems. These are real trade-offs, not marketing spin.

What the US does not get for its premium spending: better population health outcomes. Life expectancy in the US is lower than in most peer countries. Infant mortality is higher. Rates of preventable disease are comparable to or worse than countries that spend half as much per person. The value equation — outcomes relative to spending — is where the US system performs most poorly by international comparison.

A Note on Insurance Company Profits

Insurer profit is real, but it's not the dominant cost driver. Federal law (the Affordable Care Act's Medical Loss Ratio rule) requires insurers in the individual and small group markets to spend at least 80% of premium revenue on actual medical care. Large group plans must spend 85%. If they fall short, they must issue rebates to policyholders. This caps how much insurers can extract in profit, but it does nothing to control what the underlying care costs — which is the larger problem.

Additionally, many large employers don't actually buy insurance in the traditional sense. They "self-fund" — meaning they pay employee medical claims directly out of company funds and hire an insurer only to administer the plan and provide access to a provider network. For these employers, insurer profit margin is essentially irrelevant to cost. What drives their spending is the price of the care their employees actually use. You can learn more about how this structure interacts with the broader insurance market in our overview of how the ACA works and what it does and doesn't regulate.

The Role of Industry Lobbying

The health insurance and pharmaceutical industries together represent some of the largest lobbying spenders in Washington. PhRMA (the pharmaceutical industry's trade group) and the American Hospital Association consistently rank among the top lobbying organizations by spending. This sustained political investment has shaped the regulatory environment — maintaining the prohibition on Medicare drug negotiation for decades, limiting price transparency requirements, and influencing the design of benefit rules. This is a factual description of how the system has been maintained, not a political argument about what should replace it.

What Would Actually Have to Change?

There is no single lever. Reducing US healthcare costs to peer-country levels would require movement on multiple fronts simultaneously: restructuring medical education costs, building a more coherent drug pricing negotiation mechanism, simplifying billing and prior authorization rules, and creating genuine price transparency so markets can function. None of these changes is simple, fast, or politically frictionless. Understanding the structure, however, is where every realistic conversation about change has to start.

If you're currently navigating high insurance costs, the most useful next steps are: review whether your current plan's cost-sharing structure makes sense for your actual healthcare use, understand what your employer's plan actually covers and whether a high-deductible option with an HSA fits your situation, and know your rights when claims are denied — including the right to appeal and the right to request an itemized bill from any provider.

Sources: OECD Health Spending Data, KFF International Health Policy, CMS National Health Expenditure Data